The impact of migraine on daily activities: effect of topiramate compared with placebo

References

• Stewart WF, Shechter A, Lipton RB. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology 1994;44(Suppl 4):S24–S39
   Google Scholar
• Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646–57
   PubMed Web of Science ®Google Scholar
• Calvert MJ, Freemantle N. Use of health-related quality of life in prescribing research. Part 1: why evaluate health-related quality of life? J Clin Pharm Ther 2003;28(6):513–21
   Google Scholar
• Jhingran P, Osterhaus JT, Miller DW, et al. Development and validation of the Migraine-Specific Quality of Life Questionnaire. Headache 1998;38:295–302
   PubMed Web of Science ®Google Scholar
• Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Intern Med 1993;118:622–9
   Google Scholar
• Solomon GD. Evolution of the measurement of quality of life in migraine. Neurology 1997;48(Suppl 3):S10–S15
   PubMed Web of Science ®Google Scholar
• Cohen JA, Beall D, Beck A, et al. Sumatriptan treatment for migraine in a health maintenance organization: economic, humanistic, and clinical outcomes. Clin Ther 1999;21(1): 190–204
   PubMed Web of Science ®Google Scholar
• Jhingran P, Cady RK, Rubino J, et al. Improvements in health-related quality of life with sumatriptan treatment for migraine. J Fam Pract 1996;42(1):36–42
   PubMed Web of Science ®Google Scholar
• Lofland JH, Johnson NE, Batenhorst AS, Nash DB. Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective. Arch Intern Med 1999;159(8):857–63 [erratum in: Arch Intern Med 1999;159(18):2228]
   Google Scholar
• Mushet GR, Miller D, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache 1996;36(3):137–43
   PubMed Web of Science ®Google Scholar
• Martin BC, Pathak DS, Sharfman MI, et al. Validity and reliability of the migraine-specific quality of life questionnaire (MSQ Version 2.1). Headache 2000;40(3):204–15
   Google Scholar
• Solomon GD, Skobieranda FG, Gragg LA. Quality of life and well-being of headache patients: measurement by the medical outcomes study instrument. Headache 1993;33(7):351–8
   Google Scholar
• Essink-Bot ML, van Royen L, Krabbe P, Bonsel GJ, Rutten FF. The impact of migraine on health status. Headache 1995;35(4):200–6
   Google Scholar
• Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: the ID Migraine validation study. Neurology 2003;61:375–82
   PubMed Web of Science ®Google Scholar
• Terwindt GM, Ferrari MD, Tijhuis M, et al. The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000;55:624–9
   PubMed Web of Science ®Google Scholar
• Osterhaus JT, Townsend RJ, Gandek B, Ware Jr JE. Measuring the functional status and well-being of patients with migraine headache. Headache 1994;34(6):337–43
   Google Scholar
• Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004;61: 490–5
   Google Scholar
• Brandes JL, Saper JR, Diamond M, et al. Topiramate for migraine prevention: a randomized controlled trial. J Am Med Assoc 2004;291:965–73
   PubMed Web of Science ®Google Scholar
• Diener HC, Tfelt-Hansen P, Dahlof C, et al; MIGR-003 Study Group. Topiramate in migraine prophylaxis – results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004;251:943–50
   Google Scholar
• Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30(6):473–83
   Google Scholar
• Fairclough DL, Gagnon D, Papadopoulos G. Planning analyses of quality-of-life studies: a case example with migraine prophylaxis. J Biopharm Stat 2004;14:31–51
   Google Scholar
• Hochberg, Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988;75:800–2
   Web of Science ®Google Scholar
• International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. Cephalalgia 1999;11:1–12
   Google Scholar
• Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. American Academy of Neurology. US Headache Consortium. 2000. Available at http://www.aan.com/professionals/practice/ guideline/index.cfm [accessed October 2005]
   Google Scholar
• Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol 1995;52:281–6
   PubMed Web of Science ®Google Scholar
• Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17:103–8
   PubMed Web of Science ®Google Scholar
• Ware JE, Kosinski M, Gandek B. SF-36® health survey: manual and interpretation guide. Lincoln (RI): QualityMetric Inc.; 2005
   Google Scholar
• Lipton RB, Liberman JN, Kolodner KB, et al. Migraine headache disability and health-related quality-of-life: a population-based case-control study from England. Cephalalgia 2003;23: 441–50
   PubMed Web of Science ®Google Scholar